Lifecore Biomedical, Inc. (LFCR)
(Delayed Data from NSDQ)
$4.72 USD
0.00 (0.00%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $4.73 +0.01 (0.21%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LFCR 4.72 0.00(0.00%)
Will LFCR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LFCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LFCR
Lifecore (LFCR) Down 30% on Ending Strategic Review With No Deal
Strength Seen in Lifecore Biomedical (LFCR): Can Its 16.0% Jump Turn into More Strength?
LFCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vanda Pharmaceuticals (VNDA) Reports Break-Even Earnings for Q3
Will Lifecore Biomedical (LFCR) Report Negative Q1 Earnings? What You Should Know
Lifecore Biomedical (LFCR) Reports Q4 Loss, Tops Revenue Estimates
Other News for LFCR
Lifecore Biomedical: No Sale Soon Amidst Leverage And Uncertainty
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Graham & Doddsville Spring 2024 Newsletter From Columbia Business School
Lifecore Biomedical Completes Incremental Liquidity Initiatives
Lifecore Biomedical Asset Transfer for Creditor Settlement